Contributions
Abstract: EP1338
Type: ePoster
Abstract Category: Clinical aspects of MS - Diagnosis and differential diagnosis
Objective: To determine the value of the ratio between spinal cord lesion and its spinal segment length instead of using the traditional length of the vertebral body segment for diagnosis of neuromyelitis optica spectrum disorders (NMOSD)
Materials and methods: Retrospective study of the patients attending the Multiple Sclerosis Clinic and Related Disorders at Siriraj Hospital during 2005 and 2015 was performed. Inclusion criteria were those older than 15 years who satisfied the NMOSD diagnostic criteria 2015, had AQP4-antibody testing and had at least an attack of myelitis with available films to be reviewed. The ratio of spinal cord lesions were analyzed for the ratio between length of the lesion and its spinal segment involved for diagnosis AQP4 antibody positive NMOSD.
Results: Among the 64 NMOSD patients, 55 were positive and 9 were negative for AQP4 antibodies. The AQP4-seropositive NMOSD group significantly showed long spinal lesions, more often found at the cervico-thoracic regions and with centrally located. The ratio of spinal lesion to the whole length of spinal cord, alone, with the ratio of 0.10 had comparable sensitivity (95.8%) but higher specificity (81.8%) to differentiate seropositive NMOSD from MS patients compared to current use of 3 or more than vertebral segment length.
Conclusion: The length ratios of spinal lesions to the whole length of spinal cord can used for diagnosis NMOSD from MS in who presenting with TM.
Disclosure:
Dr. Chulapimphan, has nothing to disclose.
Dr. Dumrikarnlert has nothing to disclose.
Dr. Siritho has received funding for travel and speaker honoraria from Merck Serono, Pacific Healthcare (Thailand), Menarini (Thailand), Biogen Idec, UCB (Thailand) and Novartis.
Dr. Ngamsombat has nothing to disclose.
Dr. Prayoonwiwat has received funding for travel and received speaker honoraria from Bayer Schering Pharma, Eisai Inc, Pfizer Pharmaceutical Company Limited, Novartis, Sanofi-Aventis.
Abstract: EP1338
Type: ePoster
Abstract Category: Clinical aspects of MS - Diagnosis and differential diagnosis
Objective: To determine the value of the ratio between spinal cord lesion and its spinal segment length instead of using the traditional length of the vertebral body segment for diagnosis of neuromyelitis optica spectrum disorders (NMOSD)
Materials and methods: Retrospective study of the patients attending the Multiple Sclerosis Clinic and Related Disorders at Siriraj Hospital during 2005 and 2015 was performed. Inclusion criteria were those older than 15 years who satisfied the NMOSD diagnostic criteria 2015, had AQP4-antibody testing and had at least an attack of myelitis with available films to be reviewed. The ratio of spinal cord lesions were analyzed for the ratio between length of the lesion and its spinal segment involved for diagnosis AQP4 antibody positive NMOSD.
Results: Among the 64 NMOSD patients, 55 were positive and 9 were negative for AQP4 antibodies. The AQP4-seropositive NMOSD group significantly showed long spinal lesions, more often found at the cervico-thoracic regions and with centrally located. The ratio of spinal lesion to the whole length of spinal cord, alone, with the ratio of 0.10 had comparable sensitivity (95.8%) but higher specificity (81.8%) to differentiate seropositive NMOSD from MS patients compared to current use of 3 or more than vertebral segment length.
Conclusion: The length ratios of spinal lesions to the whole length of spinal cord can used for diagnosis NMOSD from MS in who presenting with TM.
Disclosure:
Dr. Chulapimphan, has nothing to disclose.
Dr. Dumrikarnlert has nothing to disclose.
Dr. Siritho has received funding for travel and speaker honoraria from Merck Serono, Pacific Healthcare (Thailand), Menarini (Thailand), Biogen Idec, UCB (Thailand) and Novartis.
Dr. Ngamsombat has nothing to disclose.
Dr. Prayoonwiwat has received funding for travel and received speaker honoraria from Bayer Schering Pharma, Eisai Inc, Pfizer Pharmaceutical Company Limited, Novartis, Sanofi-Aventis.